drugset / Trial / NCT01231607

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

NCT01231607

Phase 3 Completed 917 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

Timeline

Start
2010-10-28
Primary completion
2012-02-01
Completion
2012-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dutasteride Small molecule 0.02 mg Oral
Comparator Dutasteride Small molecule 0.1 mg Oral
Comparator Dutasteride Small molecule 0.5 mg Oral
Comparator Finasteride Small molecule 1 mg Oral

Indications